This information is intended for US healthcare professionals.

Proactive Screening

Screening can reduce DKA at onset by ≥50%1,2

Diabetic ketoacidosis (DKA) is a serious event, but screening can identify patients who may be at increased risk3

Screening for islet autoantibodies has been shown to reduce the incidence of DKA at diagnosis of Stage 3 T1D by ≥50%.1,2

Reduce incidence of DKA icon
Patients who were screened experienced an ~8x lower likelihood of DKA at clinical onset of Stage 3 T1D.4
  • ~30% to ~50% of children in the United States experience DKA at the onset of Stage 3 T1D5
  • Children with moderate or severe DKA were less likely to experience a “honeymoon phase” than children without DKA at diagnosis6

Metabolic scarring

DKA at onset may cause a “metabolic scar” in patients, which can lead to worse metabolic control in the short and longer term.3

Metabolic and physical consequences of DKA at onset

  • Lower residual beta-cell function3,6
  • Higher HbA1c for at least 15 years7
  • Rare neurological trauma such as cerebral edema8

Early identification can improve outcomes at Stage 3 T1D onset

Screening can help identify patients who might benefit from enhanced clinical vigilance and education, which can improve management at Stage 3 T1D onset.3

Percent of children presenting with DKA4

Screening vs. non-screening DKA graphicScreening vs. non-screening legend

Average A1c at Stage 3 T1D onset in screened vs non‑screened children4,9

Screening vs non-screening A1C graphic
Screening vs. non-screening legend

Screening family members can help identify potential patients for upcoming trials and novel therapy candidates

See How
References

1. Barker JM, Goehrig SH, Barriga K, et al; DAISY study. Clinical characteristics of children diagnosed with type 1 diabetes through intensive screening and follow-up. Diabetes Care. 2004;27(6):1399-1404.

2. Elding Larsson H, Vehik K, Bell R, et al. Reduced prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes in young children participating in longitudinal follow-up. Diabetes Care. 2011;34(11):2347-2353.

3. Raab J, Haupt F, Scholz M, et al; Fr1da Study Group. Capillary blood islet autoantibody screening for identifying pre-type 1 diabetes in the general population: design and initial results of the Fr1da study. BMJ Open. 2016;6(5):1-12.

4. Winkler C, Schober E, Ziegler A-G, Holl RW. Markedly reduced rate of diabetic ketoacidosis at onset of type 1 diabetes in relatives screened for islet autoantibodies. Pediatr Diabetes. 2012;13(4):308-313.

5. Rewers A, Dong F, Slover RH, Klingensmith GJ, Rewers M. Incidence of diabetic ketoacidosis at diagnosis of type 1 diabetes in Colorado youth, 1998-2012. JAMA. 2015;313(15):1570-1572.

6. Neylon OM, White M, Connell MAO, Cameron FJ. Insulin-dose-adjusted HbA1c-defined partial remission phase in a paediatric population—when is the honeymoon over? Letter. Diabet Med. 2013;30(5):627-628. doi:10.1111/dme.12097

7. Duca LM, Wang B, Rewers M, Rewers A. Diabetic ketoacidosis at diagnosis of type 1 diabetes predicts poor long-term glycemic control. Diabetes Care. 2017;40(9):1249-1255.

8. Glaser N, Barnett P, McCaslin I, et al; for The Pediatric Emergency Medicine Collaborative Research Committee of the American Academy of Pediatrics. Risk factors for cerebral edema in children with diabetic ketoacidosis. N Engl J Med. 2001;344(4):264-269.

9. Centers for Disease Control and Prevention. All About Your A1C. Accessed December 2, 2022. https://www.cdc.gov/diabetes/managing/managing-blood-sugar/a1c.html